Cancer Center

ANNUAL REPORT2017

Cancer is a long journey and, for thousands of survivors, the Memorial Healthcare Cancer Center is where it begins. Our center is proud to offer area patients sophisticated technology and expertise right here in Owosso. Services are provided in a unique healing environment designed for wellness, hope and possibilities by a dedicated team of highly skilled hematology/oncology and radiation oncology physician specialists who work collaboratively with an outstanding team of oncology nurses.

2017 Memorial Healthcare Cancer Center Highlights:• Increased use of oral chemotherapy drugs and the need for close lab and telephone follow-up• The Annual Cancer Survivor Day event was held in June to celebrate our cancer survivors. Attendees

enjoyed an ice cream social, live entertainment, guest speakers, raffles and more.• There were many advances in immunotherapy during 2017 for multiple cancers including lung,

bladder, lymphoma, kidney, brain and liver cancer• FREE Cancer screening events were increased to twice a year for the public and on an as needed

basis for individuals during the year. These events were funded through the support of the MemorialHealthcare Foundation Cancer Screening Fund, Corunna Rotary Club and numerous MemorialCancer Center physicians and employees.

• Several Lunch and Learn events were held at the Cancer Center in 2017. These events providedthe community with opportunities to learn about educational topics and health information fromprofessionals at Memorial Healthcare

• A Medical Oncology Conference was provided for staff and providers to obtain CME hours• New Social Worker

– Look Good Feel Better Program– Provided staff enrichment opportunities

• Patient satisfaction scores continued to be above the 90th percentile• Continuation of our HOPE (Helping Oncology Patients Early) program

2017 has been another exceptional year of accomplishments and tremendous growth. As you look through this report you will see inspiring examples of the many activities that have taken place at our Cancer Center. The Memorial Healthcare Cancer Center strives to be a leader in providing patients with highest-quality cancer care using the most sophisticated technology and expertise in our region. It is an honor to provide our patients with the best cancer care.

We are forever grateful for the continued support of the community who help up in providing the best in cancer care to our patients. We look forward to another great year of success and growth as a prominent destination of choice for cancer services. On behalf of our team, we proudly present the 2017 Memorial Healthcare Cancer Center Annual Report.

Tallat Mahmood, MDCancer Center Medical Director

DARK BLUEMarch is Colon Cancer Awareness MonthDARK BLUEMarch is Colon Cancer Awareness Month2

MemorialHealthcare.org/services/cancercenter

Cancer Center

3

Daniel Williams, MD, MSBoard Certified Internal Medicine, Medical Oncology, Palliative and Hospice, and Toxology

Hesham Gayar, MDBoard Certified Radiation Oncology

Tallat Mahmood, MDMedical DirectorBoard Certified Hematology, Internal Medicineand Medical Oncology

Jack Nettleton, MD Board CertifiedRadiation Oncology

Ronald Kawauchi, MD Board Certified Medical Oncology and Hematology

Kiran Devisetty, MD Board Certified Radiation Oncology

MEDICAL & RADIATION ONCOLOGISTS

Elaine McNamara, MSN, FNP-BCBoard CertifiedFamily Nurse Practitioner

ADVANCED PRACTICE PROVIDER

MEDICAL DIRECTOR

BURGUNDYMarch is Multiple Myeloma Cancer Awareness Month

BURGUNDYMarch is Multiple Myeloma Cancer Awareness Month

4 ORANGEMarch is Kidney Cancer Awareness MonthORANGEMarch is Kidney Cancer Awareness Month

PROFESSIONAL EDUCATION & STAFF SUPPORT

The Power of Compassion Memorial Healthcare, October 11 & 12, 2017

Catagorizing Pain Types and Providing Appropriate Interventions, New Genetic Concepts of AJCC TNM Cancer StagingMemorial Healthcare Oncology Conference November 9, 2017

Jaime Ritter, RN, BSN, OCN, Director of Cancer Center (left) and Elaine McNamara, MSN, FNP-BC (right).

CONFERENCES ATTENDED

Medical/Legal Ethics (Florida)Attended by Elaine McNamara, MSN, FNP-BC, Nurse Practitioner

Association of Community Cancer Centers Annual Conference (Nashville, TN)Attended by Elaine McNamara, MSN, FNP-BC, Nurse Practitioner; Jaime Ritter, RN, BSN, OCN; Jeanie Rye, MBA, CMOM

MSHO Great Lakes Cancer Conference (Lansing) Attended by Elaine McNamara, MSN, FNP-BC, Nurse Practitioner; Jaime Ritter, RN, BSN, OCN; Amber Eickholt, RN, BSN; Michelle Holcomb, RN OCN; Jan Burns, RN; Erica Springsdorf, RN; Kate McCaw, RN, BSN

MD/Anderson/Coveanant Healthcare Advances in 12 Attended by Elaine McNamara, MSN, FNP-BC, Nurse Practitioner; Jaime Ritter, RN, BSN, OCN; Amber Eickholt, RN, BSN

Comprehensive OCN ReviewAttended by Amber Eickholt, RN, BSN

Michigan Cancer Registrars Association Annual Educational Conference (Bay City)Attended by Lynnea Malatinsky, RHIT, CTR

Certification for Hematology/Oncology Managers (Livonia)Testing done by Jeanie Rye, MBA, CMOM

TUMOR BOARD AND BREAST BOARD CONFERENCE 2017 ATTENDANCE REPORT

2017 Presentations: 92 cases presented

Attendance: Medical Oncology 100% Surgeons 90% Pathology 100% Radiation Oncology 100% Radiology 100%

Clinical Staging Guidelines were discussed and documented at Tumor and Breast Board Conferences with 92 cases presented. Treatment planning, using evidence-based treatment guidelines, were also discussed among the multidisciplinary attendance.

5LIME GREENSeptember is Lymphoma Cancer Awareness Month

LIME GREENSeptember is Lymphoma Cancer Awareness Month

Bayer Chronos 3: A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Copanlisib in combination with Rituximab in patients with relapse indolent B-cell non-Hodgkin’s lymphoma

Bayer Chronos 4: Intravenous PI3K inhibitor Copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapse indolent Non-Hodgkin’s Lymphoma

MEI: A two-stage, open label followed by a placebo-controlled phase II study of Pracinostatand Azacitidine in patients with IPSS-R high and very high risk Myelodysplastic Syndromes previously untreated with hypomethylating agents

NATIONAL CLINICAL TRIALS

Boehringer Ingelheim: Phase III, randomized, double-blind trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Bevacizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer

Novartis: SOLAR-1: A phase III randomized double-blind placebo controlled study of Alpelisib in combination with Fulverstrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromotase inhibitor treatment

Protalex: A phase 1/2, open-label, dose escalation study of PRTX-100 in adult patients with persistant/chronic immune Thrombocytopenia

RESEARCH

Patients of Memorial Healthcare’s Cancer Center have the option of participating in clinical trials. Clinical studies help bridge research and patient care by evaluating therapies, drugs and diagnostic tools to drive discoveries into clinical practice. The oncologists at Memorial Healthcare are impassioned in conducting clinical research to advance cancer treatment standards with the goal of helping patients live longer, healthier lives. The research trials are conducted in collaboration with Detroit Clinical Research Center, Farmington Hills, MI.

6 LIGHT BLUESeptember is Prostate Cancer Awareness MonthLIGHT BLUESeptember is Prostate Cancer Awareness Month

CANCER COMMITTEE

The Cancer Committee is a standing committee of Medical Oncology and Medical Radiation staff. The committee meets quarterly to plan, assess and implement all cancer-related programs and activities at the hospital. The committee’s goals ensure Memorial Healthcare offers a coordinated, multidisciplinary approach to cancer prevention and treatment supported by state-of-the-art technology and specially-trained staff. The committee strives to continually improve patient survival and outcomes to enhance the quality of life for all cancer patients, regardless of diagnosis. These goals are accomplished by an emphasis on wellness, education, prevention,

2017 CANCER COMMITTEE GOALS

PROGRAMMATIC GOALS• ImplementationofLungCancerScreeningProgramat

the Cancer Center

CLINICAL GOALS• Improvedocumentatio,monitoringadtreatmentof

pain for all cancer patients by the end of 2017

CANCER COMMITTEE 2017 ATTENDANCE REPORTJanuary 26, 2017: Physician 90% Non-physician 88%

April 27, 2017: Physician 80% Non-Physician 93%

July 27, 2017: Physician 60% Non-Physician 75%

October 26, 2017: Physician 80% Non-Physician 93%

Background: this Web-based Cancer Program Practice Profile Reports (CP3R) offers local providers comparitive information to assess adherance to and consideration of standard of care therapies for major cancers. This reporting tool provides a platform from which to promote continuous practice improvements to improve quality of patient care at the local level and also permits hospitals to compare their care for those patients relative to that of other providers.

CoC Std./% Estimated Performance Rates (%)2013 2014 2015

4.5/85% 100 83.3 100

Not applicable 100 100 100

Select Measures

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Quality Improvement)

Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC statge III (lymph node positive) colon cancer (Accountability)

CANCER PROGRAM PRACTICE REPORT (CP3R) – COLON CANCER

7

CANCER COMMITTEE 2017 ATTENDANCE REPORTJanuary 26, 2017:

Physician 90% Non-physician 88%

April 27, 2017: Physician 80% Non-Physician 93%

July 27, 2017: Physician 60% Non-Physician 75%

October 26, 2017: Physician 80% Non-Physician 93%

PHYSICIAN MEMBERSKiran Devisetty, MDPhysician Liaison

Lisa LePain, DOGastroenterologist

Ronald Kawauchi, MDMedical Oncology

Suzanne Law, DOSurgeon

Tallat Mahmood, MDMedical Oncology

Keith Morrow, DORadiologist

Margaret Purdy, MS, MDGeneral Internist

Ernesto Quiachon, MD, FCAP, FASCP, MIACPathologist

Douglas Strong, MDFamily Physician

Daniel Williams, MDCancer Committee Chair

ORANGESeptember is Leukemia Cancer Awareness Month

ORANGESeptember is Leukemia Cancer Awareness Month

NON-PHYSICIAN MEMBERSJim Barb, MBA, CPHOChief Experience Officer

Kim Belous, RN, OCNRadiation Oncology Clinical Coordinator

Kevin Davis, CMPR, MS, OTRAssociate Vice President (Ancillary Services)

Amber Eickholt, RN, BSNNurse Navigator

Caitlin Freeman, LLMSWSocial Service

Lynnea Malatinsky, RHIT, CTRTumor Registrar

Elaine McNamara, MSN, FNP-BC Palliative Care

Stephanie Molnar, LLMSWSocial Service

Becky Nickels, RN, BSNClinical Research Coordinator

Mindi OdomAmerican Cancer Society

Marla Price, RDDietitian

Lorna Quirk, RNInpatient Nurse Manager

Jaime Ritter, RN, BSN, OCNDirector, Cancer Center

Kathy Roberts, RN, BA Outpatient Services Care Director

Yvonne Robles, RNCase ManagementRev. Ray StrawserSpiritual Counselor

CANCER COMMITTEE 2017

CoC Std./% Estimated Performance Rates (%)2013 2014 2015

4.4/90% 100 100 95

4.4/90% 100 100 100

4.4/90% 100 100 No data

4.5/80% 90.3 96.7 89

Not applicable 94.4 73.7 90

Not applicable 100 100 100

Select Measures

Radiation administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability)

Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability)

Raditation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >=4 positive regional lymph nodes (Accountability)

Image or palpatation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer (Quality Improvement)

Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II Breast cancer (Surveillance)

Combination chemotherapy is recommended or adminstered within 4 months (120 days) of diagnosis for women under 70 with AJCC TIcNO, or Stage IB-III hormone receptor negative breast cancer (Accountability)

CANCER PROGRAM PRACTICE REPORT (CP3R) – BREAST CANCER

TEALSeptember is Ovarian Cancer Awareness MonthTEALSeptember is Ovarian Cancer Awareness Month8

2017 COMMUNITY OUTREACHRelay for Life (June)Raised over $10,000 for the American Cancer Society

Cancer Survivor Celebration (June)60 people attended

“Support the Foundation” Art Bra Event (August) Raised over $11,800 which will enable the Memorial Healthcare Foundation to provide cancer screenings to community members in the Shiawassee region.

Breast Screening (November)18 women screened, 2 men screened

Colorectal Screening (November)26 kits distributed

Prostate Screening (November)11 men screened

Skin Screening (November)33 people screened

Lung Screening (CT Scan) (ongoing)234 people screened

CANCER SCREENINGS

Early detection of certain cancers can save lives, reduce extent of treatment and improve quality of life. Screenings offered by Memorial Healthcare in 2017 were:

• Breast• Colorectal• Prostate• Skin

Screening services reached 45 individuals who had no primary care physician and/or who have not received screening tests within one year. The purpose of these programs was to help in the prevention, early detection and treatment of cancer.

Cancer Survivor Day Celebration

Community Cancer Screenings are provided in conjunction with Memorial Healthcare Foundation and the Community Cancer Fund.

9TEAL, PINK & BLUESeptember is Thyroid Cancer Awareness Month

TEAL, PINK & BLUESeptember is Thyroid Cancer Awareness Month

Richard Lahmann volunteers his time playing the piano at the Memorial Cancer Center.

COMMUNITY SUPPORT GROUPS

US TOO! Prostate Support Group — A support group for men who have faced or are currently facing prostate cancer. Supportive family/friends are also invited to attend. The group meets the 3rd Monday of each month.

Life Goes On — A support group for people who have faced or are currently facing any type of cancer. This group also includes friends, family and caregivers. The group meets the 1st Monday of each month.

Look Good… Feel Better — This nationwide program is provided through a partnership with the American Cancer Society, National Cosmetology Association and Personal Care Products Foundation. This progam teaches women how to cope with skin changes and hair loss that may occur during treatment for cancer. The sessions are held the 2nd Monday of each month.

Breast Cancer Support Group “The Pink Brick Road” — A support group for those who are currently facing or have faced Breast Cancer. Supportive family/friends are also invited to attend. (Meets with Life Goes On)

Reach To Recovery — A personal support program sponsored by the American Cancer Society that partners breast cancer patients with survivors who have similar cancer journeys.

Music Therapy — Several days a week, members of the community come to share their talent to play soothing music on the baby grand piano located in the lobby of the Medical Arts Building.

ANALYTICAL LUNG CANCER BY YEARLUNG CANCER CASES - MEMORIAL HEALTHCARE

2013 - 2017

0

10

20

30

40

50

2014 2015 2016 2017

50 PTS.

2013

42 PTS.45 PTS. 44 PTS.

ANALYTICAL BREAST CANCER BY YEARBREAST CANCER CASES - MEMORIAL HEALTHCARE

2013 - 2017

2016 20162013 2014 2015

43 PTS.51 PTS.

41 PTS.42 PTS.

64 PTS.

0

10

20

30

40

50

60

7053 PTS.

10

2017 AGE AT DIAGNOSIS

2 PTS.1%

5 PTS.2%

39 PTS.18%

10 PTS.4%

64 PTS.28%

69 PTS.31%

34 PTS.15%

3 PTS.1%

0-29 30-39 40-49 50-59 60-69 70-79 80-89 90+

AGE

0

10

20

30

40

50

60

70

PEARLSeptember is Mesothelioma Cancer Awareness MonthPEARLSeptember is Mesothelioma Cancer Awareness Month

SHIAWASSEE

SAGINAW

GENESEE

CLINTON

INGHAM

OTHER

2017 COUNTY AT DIAGNOSIS

5 PTS - 2%

2 PTS - 1%

5 PTS - 2%

21 PTS - 9%9 PTS - 4%

184 PTS - 82%

2017 TOP FIVE CANCER SITES

51 PTS53 PTS

13 PTS

14 PTS 24 PTS

PROSTATE

BREAST

LUNG

COLON/RECTUM/RECTOSIGMOID

URINARY BLADDER

ANALYTICAL LUNG CANCER BY YEARLUNG CANCER CASES - MEMORIAL HEALTHCARE

2013 - 2017

0

10

20

30

40

50

2014 2015 2016 2017

50 PTS.

2013

42 PTS.45 PTS. 44 PTS.

ANALYTICAL BREAST CANCER BY YEARBREAST CANCER CASES - MEMORIAL HEALTHCARE

2013 - 2017

2016 20162013 2014 2015

43 PTS.51 PTS.

41 PTS.42 PTS.

64 PTS.

0

10

20

30

40

50

60

7053 PTS.

PINKOctober is Breast Cancer Awareness Month

PINKOctober is Breast Cancer Awareness Month11

2017 PRIMARY SITE TABLE

PRIMARY SITE TOTAL MALE FEMALE ANALYTICNON-

ANALYTIC ALIVE EXPIRED

Oral Cavity & Pharynx 4 2 2 4 0 3 1Esophagus 3 1 2 3 0 0 3Stomach 2 2 0 2 0 1 1Small Intestine 1 0 1 1 0 1 0Colon 8 3 5 8 0 5 3Rectum & Rectosigmoid 5 4 1 5 0 5 0Anus, Anal Canal & Anorectum 4 0 4 4 0 3 1Liver & Intrahepatic Bile Duct 5 4 1 5 0 3 2Gallbladder 2 0 2 2 0 0 2Pancreas 3 2 1 3 0 1 2Larynx 1 1 0 1 0 0 1Lung & Bronchus 53 29 24 53 0 29 24Bones & Joints 1 1 0 1 0 1 0Soft Tissue 1 1 0 1 0 1 0Melonoma-Skin 11 5 6 4 7 11 0Breast 51 0 51 51 0 50 1Cervix Uteri 20 0 20 2 18 19 1Corpus & Uterus, NOS 7 0 7 7 0 7 0Ovary 3 0 3 3 0 3 0Vulva 2 0 2 1 1 1 1Prostate 24 24 0 24 0 23 1Penis 1 1 0 1 0 1 0Urinary Bladder 14 8 6 14 0 12 2Kidney & Renal Pelvis 6 1 5 6 0 5 1Thyroid 1 0 1 1 0 1 0Lymphoma 10 4 6 9 1 9 1Myeloma 2 1 1 2 0 2 0Leukemia 3 1 2 2 1 2 1Miscellaneous 5 1 4 5 0 0 5

Total 253 96 157 225 28 196 53

GREENOctober is Liver Cancer Awareness MonthGREENOctober is Liver Cancer Awareness Month

TUMOR REGISTRAR

Employees in the cancer registry are skilled healthcare professionals who apply clinical and technical knowledge to maintain a comprehensive database on cancer related information. They collect specific data on all cancer cases diagnosed and/or treated at Memorial Healthcare. Detailed data elements collected include the primary cancer site, cancer stage, histology, treatment information and numerous other items. Key information is collected at the time of diagnosis and for the lifetime of the patient. Accuracy and timeliness of the data is critical in order to maintain required standards and to support research and education. In order to accomplish the above, registrars work closely with physicians, the patient medical record and many other healthcare professionals from within and outside Memorial Healthcare.

The registry staff are also involved in managing, abstracting, analyzing and the reporting of cancer data for trends and outcomes. In addition, their responsibilities

include preparation of our annual cancer program report, coordinating and attending weekly tumor conferences and quarterly cancer committee meetings, as well as the management of the required cancer program standards. As mandated by the State of Michigan, our cancer data is submitted regularly to the state registry and to the National Cancer Data Base (NCDB). The staff works diligently to meet or exceed the American College of Surgeons – Commission on Cancer (ACoS-CoC) standards and organizational goals.

ANALYTIC CASES BY CLASS OF CASE (COC)

The cancer registry often times refers to the number of cancer cases in terms of analytic or non-analytic cases. In addition, these cases are further defined by class of case. Analytic cases are those who have been diagnosed and/or have had all or some of their first course of treatment at Memorial Healthcare. The data collected for analytic cases are detailed and included in treatment and survival analysis. The table below illustrates how each analytic case is categorized by what is described as class of case or the nature of the involvement that Memorial Healthcare has in the care of each patient.

THE CANCER REGISTRY PROGRAMLynnea Malatinsky, RHIT, CTR

COC TOTAL TOTAL CODE DESCRIPTION OF ANALYTIC (CLASS OF CASE –CoC) # %

00 Initial diagnosis at Memorial Healthcare and all treatment or 52 23%a decision not to treat was done elsewhere

10 Initial diagnosis at Memorial Healthcare or staff physician’s office and part or all of 7 3%first course treatment or a decision not to treat done at Memorial Healthcare

11 Initial diagnosis in staff physician’s office and part of first course treatment was done 1 .5%at Memorial Healthcare

12 Initial diagnosis in staff physician’s office and all of first course treatment 1 .5%or decision not to treat was done at Memorial Healthcare

13 Initial diagnosis at Memorial Healthcare and part of first course treatment 18 8%was done elsewhere

14 Initial diagnosis at Memorial Healthcare and all first course treatment 122 54%or decision not to treat was done at Memorial Healthcare

20 Initial diagnosis elsewhere and all or part of first course treatment was 7 3%done at Memorial Healthcare

21 Initial diagnosis elsewhere and part of first course treatment was done 13 6%at Memorial Healthcare, part of first course treament was done elsewhere

22 Initial diagnosis elsewhere and all first course treatment or a decision not to treat was 4 2%done at Memorial Healthcare

Total 225 100%

12

PURPLENovember is Pancreatic Cancer Awareness Month

PURPLENovember is Pancreatic Cancer Awareness Month

Accession – an eight-digit number assigned to each case which indicates the first year the patient was seen at the institution for diagnosis and/or treatment of cancer and the numeric order in which the registry entered the case into the database.

Analytic – first diagnosed at reporting hospital since its reference date and either received all or part of first course of therapy at the hospital.

Cancer Registry – An information system designed for the collection, management and analysis of data on persons with the diagnosis of a malignant or neoplastic disease (cancer).

Distant – Neoplasm which spreads to parts of the body remote from primary tumor, either by extension or discontinuous metastasis to distant organs, tissues or lymph nodes.

Emetogenic – having the capacity to induce emesis (vomiting); a common side effect of anticancer agents.

Histology – Study of the microscopic structure of tissue.

Initial Treatment/Therapy – All treatment/therapies within the first four months following diagnosis.

In Situ – Neoplasm meets all microscopic criteria for malignancy, except Invasion.

Localized – Neoplasm that appears entirely confined to organ of origin.

Medical Oncology – Includes chemotherapeutic drugs and hormones administered singly or in combination.

Medical Registry Services, Inc. (MRS) – cancer data management system for entering and maintaining all oncology patient information.

National Cancer Database (NCDB) – National hospital registries submit data from their database to this central registry for studies.

Neoplasm – A new and abnormal formation of tissue, as a tumor or growth which serves no useful function but grows at the expense of the healthy organisms.

Non-Analytic – first diagnosed at another hospital and either entire first course of therapy was given elsewhere, was never treated or unknown, if treated; first diagnosed at reporting hospital before its reference date; first diagnosed at autopsy.

Oncology – the study of tumors/malignancies.

Osteonecrosis – a disease resulting from the temporary permanent loss of blood supply to the bone.

Palliative – Serving to relieve or alleviate without curing.

Patient Care Evaluation – studies of malignant diseases designed to describe the practice of medicine at the community level and to provide management and end result information; required by the Commission on Cancer, National Cancer Database.

Polyp – an abnormal growth of tissue projecting from a mucous membrane.

Primary Site – The anatomical location within the human body considered the point of origin for the malignancy.

Radiation – Cancer related or directed beam and/or non-beam. Non-beam includes radium, iridium, cesium and radioactive isotopes. Ablative hormone radiation is included.

Regional – Neoplasm extending beyond the limits of organ or origin directly into surrounding organs or tissues or into regional lymph nodes.

Reference Date – starting date after which all eligible cases must be included in the registry.

Stage of Disease – Determined at first course of treatment.

Surgery – Partial or total removal of tumor, excluding biopsy.

Unknown/Unstaged – When the stage cannot be determined from the medical record or a medical authority.

GLOSSARY OF TERMS

13

Nurse/Nurse Practitioner — The nurses are an instrumental part of cancer care. Patients connect with many nurses, from the Nurse Practitioner that assists the medical oncologist in diagnosis and treatment; to the nurses in the infusion center that administer chemotherapy and evaluate processes during treatment; to the radiation nurses who assist the radiation oncologist with symptom management, provide education on the various radiation therapy modalities, and act as case managers to coordinate patient care.

Radiation Therapist — Radiation therapists are highly trained in safe delivery of various types of radiation therapy. They interact with patients, educating them and offering support on a daily basis.

Medical Assistants — Trained medical professionals who perform clinical duties under the direction of the medical oncologist during patient office visits.

Social Worker — The social worker is a licensed professional who helps patients and family members, with any emotional, financial or physical needs.

Nurse Navigator — The Nurse Navigator is a nurse that guides patients through the healthcare system, assists in overcoming barriers, and supports patients in informed decisions regarding their care.

WHITENovember is Lung Cancer Awareness MonthWHITENovember is Lung Cancer Awareness Month14

The Memorial Cancer Center team

MEET OUR TEAM

At the Memorial Cancer Center, there are many people who are part of a team with the same goal — to give the very best in specialized oncology care. Now, let us introduce our team.

Medical Oncologist/Hematologist — The medical oncologist / hematologist is a specialist who acts as the primary physician. The medical oncologist will aide in care from time of diagnosis to treatment therapy options, to time of survivorship. The medical oncologist is responsible for the coordination of the other members of the team.

Radiation Oncologist — The radiation oncologist is a specialist who provides radiation therapy options and guides patients through their radiation treatment. The radiation oncologist works closely with the medical oncologist in all aspects of cancer care.

Radiologist — The radiologist is a specialist in the interpretation of diagnostic images. Some of the diagnostic testing includes, but not limited to, PET scan, CT scan, MRI, and Ultrasound. The Radiologists’ interpretation helps the medical oncologist and radiation oncologist to decide treatment options.

Pathologist — The Pathologist specializes in the diagnosis of the cancer disease. The Pathologist diagnoses the cancer by looking through a microscope at biopsy tissue that is typically obtained at the time of surgery. Although “behind the scene,” he/she is a key member of your team that helps the Medical Oncologist and Radiation Oncologist to decide treatment options.

PERIWINKLENovember is Stomach Cancer Awareness Month

PERIWINKLENovember is Stomach Cancer Awareness Month

MEDICAL ONCOLOGY

Memorial Cancer Center provides custom treatment plans for patients which may involve multiple modalities of therapy. Medical Oncology and Hematology services are provided by Ronald Kawauchi, MD; Tallat Mahmood, MD; Daniel Williams, MD, MS; and Elaine McNamara, MSN, FNP.

MEDICAL ONCOLOGY TREATMENTS• Chemotherapy• Hormonal therapy• Clinical trials• Targeted therapy• Genetic testing

RADIATION ONCOLOGY

A precise, expert course of radiation treatment is available to patients at the Memorial Cancer Center, in affiliation with the McLaren Cancer Institute, through technologically-advanced systems and a custom plan, developed in coordination with other cancer specialists and primary care givers.

Our radiation treatment team includes board certified radiation oncologists, physicists, physician assistants, radiation therapists, dosimetrists and oncology nurses. Chairman of Radiation Oncology, Hesham Gayar, MD, radiation oncologist Jack Nettleton, MD, and Kiran Devisetty, MD provide skilled care utilizing state-of-the-art Image-Guided Radiation Therapy (IGRT) delivery modes similar to those services found at the nation’s premiere cancer centers.

CERTIFICATIONSCommission on Cancer, accredited through 2021

Quality Oncology Practice Initiative

15

Certified through 2021

Kiran Devisetty, MD, Elaine McNamara, MSN, FNP-BC, and Jaime Ritter, RN, BSN, OCN, Director of the Cancer Center

AFFILIATIONS

American Cancer Society, Great Lakes Divisions, Inc.

Michigan Cancer Consortium – A statewide organization committed to working together to reduce the human and economic impact of cancer in Michigan

Blue Cross, Blue Shield of Michigan Oncology Care Program

Detroit Clinical Research Center, Farmington Hills, MI

Radiation Therapy: McLaren Cancer Institute Flint, MI

Friends of Hospice for Memorial Healthcare

American College of Surgeons

Association of Community Cancer Centers

Michigan Oncology Quality Consortium

I want to share the truly incredible

experience I had at the Memorial

Healthcare Cancer Center with

anyone looking for cancer

care. Every single person, I

encountered during my treatment

there, from the staff to the

doctors, was extremely

knowledgeable, warm, caring

and compassionate. They

treated me with kindness and

dignity every step of the way.

I would highly recommend the

Memorial Healthcare Cancer

Center to anyone dealing with a

cancer diagnosis. From the first

phone call to the last treatment

they treated me like family.

– Cancer Center Patient

“

” MemorialHealthcare.org

TOGETHER:A BETTER WAY TO FIGHT CANCER